Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 720

1.

Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.

Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR, Horban A, Lonjon-Domanec I, DeMasi R, Picchio G, Luo D, De Meyer S, Zeuzem S.

Liver Int. 2014 Oct 15. doi: 10.1111/liv.12703. [Epub ahead of print]

PMID:
25319731
[PubMed - as supplied by publisher]
2.

Identifying Indications for Percutaneous (PTC) vs. Endoscopic Ultrasound (EUS)- Guided "Rendezvous" Procedure in Biliary Obstruction and Incomplete Endoscopic Retrograde Cholangiography (ERC).

Albert JG, Finkelmeier F, Friedrich-Rust M, Kronenberger B, Trojan J, Zeuzem S, Sarrazin C.

Z Gastroenterol. 2014 Oct;52(10):1157-1163. Epub 2014 Oct 14.

PMID:
25313627
[PubMed - as supplied by publisher]
3.

[In Process Citation].

Lynen Jansen P, Kopp I, Nothacker M, Zeuzem S.

Z Gastroenterol. 2014 Oct;52(10):1151-2. doi: 10.1055/s-0034-1385336. Epub 2014 Oct 14. German. No abstract available.

PMID:
25313625
[PubMed - in process]
4.

Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.

Zeuzem S, Dufour JF, Buti M, Soriano V, Buynak RJ, Mantry P, Taunk J, Stern JO, Vinisko R, Gallivan JP, Böcher W, Mensa FJ; the SOUND-C3 study group.

Liver Int. 2014 Sep 29. doi: 10.1111/liv.12693. [Epub ahead of print]

PMID:
25263751
[PubMed - as supplied by publisher]
5.

A fractured duodenal self-expanding metal stent in a patient with pancreatic cancer.

Trojan J, Vogl TJ, Zeuzem S, Albert JG.

Endoscopy. 2014 0;46(S 01):E386-E387. Epub 2014 Sep 25. No abstract available.

PMID:
25254591
[PubMed - as supplied by publisher]
6.

Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B.

Leung NW, Herrmann E, Lau GK, Chan HL, So TM, Zeuzem S, Dong Y, Trylesinski A, Naoumov NV.

Infect Dis Ther. 2014 Sep 17. [Epub ahead of print]

PMID:
25228496
[PubMed - as supplied by publisher]
7.

Decade in review-HCV: Hepatitis C therapy-a fast and competitive race.

Zeuzem S.

Nat Rev Gastroenterol Hepatol. 2014 Sep 16. doi: 10.1038/nrgastro.2014.164. [Epub ahead of print] No abstract available.

PMID:
25223875
[PubMed - as supplied by publisher]
8.

Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients.

van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, Welzel TM, Zeuzem S, Lawitz EJ, Rodriguez-Torres M, Kupcova V, Wiercinska-Drapalo A, Hodges MR, Janssen HL, Reesink HW.

Antiviral Res. 2014 Sep 8;111C:53-59. doi: 10.1016/j.antiviral.2014.08.015. [Epub ahead of print]

PMID:
25218783
[PubMed - as supplied by publisher]
9.

A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial.

Albert JG, Lucas K, Filmann N, Herrmann E, Schröder O, Sarrazin C, Trojan J, Kronenberger B, Bojunga J, Zeuzem S, Friedrich-Rust M.

Endoscopy. 2014 Oct;46(10):857-61. doi: 10.1055/s-0034-1377628. Epub 2014 Sep 10.

PMID:
25208030
[PubMed - in process]
10.

Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.

Dultz G, Gerber L, Farnik H, Berger A, Vermehren J, Pleli T, Zeuzem S, Piiper A, Kronenberger B, Waidmann O.

J Viral Hepat. 2014 Sep 2. doi: 10.1111/jvh.12309. [Epub ahead of print]

PMID:
25181653
[PubMed - as supplied by publisher]
11.

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection.

Scott J, Rosa K, Fu M, Cerri K, Peeters M, Beumont M, Zeuzem S, Evon DM, Gilles L.

BMC Infect Dis. 2014 Aug 26;14:465. doi: 10.1186/1471-2334-14-465.

PMID:
25164700
[PubMed - in process]
Free PMC Article
12.

[Prof. Dr. med. Peter Galle].

Zeuzem S.

Z Gastroenterol. 2014 Aug;52(8):799-800. doi: 10.1055/s-0034-1366693. Epub 2014 Aug 11. German. No abstract available.

PMID:
25111717
[PubMed - in process]
13.

Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B.

Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL.

Aliment Pharmacol Ther. 2014 Oct;40(7):811-8. doi: 10.1111/apt.12910. Epub 2014 Aug 11.

PMID:
25109699
[PubMed - in process]
14.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourlière M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Bräu N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S.

Gut. 2014 Jul 30. pii: gutjnl-2014-307498. doi: 10.1136/gutjnl-2014-307498. [Epub ahead of print]

PMID:
25080450
[PubMed - as supplied by publisher]
15.

Anti-HDV IgM as a marker of disease activity in hepatitis delta.

Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group.

PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014.

PMID:
25072849
[PubMed - in process]
Free PMC Article
16.

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.

Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S; EMERGE study group.

J Hepatol. 2014 Jul 24. pii: S0168-8278(14)00521-2. doi: 10.1016/j.jhep.2014.07.022. [Epub ahead of print]

PMID:
25064437
[PubMed - as supplied by publisher]
17.

Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis--a prospective cohort study.

Pleli T, Martin D, Kronenberger B, Brunner F, Köberle V, Grammatikos G, Farnik H, Martinez Y, Finkelmeier F, Labocha S, Ferreirós N, Zeuzem S, Piiper A, Waidmann O.

PLoS One. 2014 Jul 25;9(7):e103532. doi: 10.1371/journal.pone.0103532. eCollection 2014.

PMID:
25062038
[PubMed - in process]
Free PMC Article
18.

Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate.

Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Mani Subramanian G, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Jenny Heathcote E.

J Hepatol. 2014 Jul 18. pii: S0168-8278(14)00518-2. doi: 10.1016/j.jhep.2014.07.019. [Epub ahead of print]

PMID:
25046847
[PubMed - as supplied by publisher]
19.

Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.

Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, Knop V, Telese A, Lenci I, Andreoli A, Zeuzem S, Angelico M.

Dig Liver Dis. 2014 Oct;46(10):923-7. doi: 10.1016/j.dld.2014.06.004. Epub 2014 Jul 3.

PMID:
24997638
[PubMed - in process]
20.

[In Process Citation].

Hézode C, Brainard D, Pol S, Libert O, Symondq W, McHutchison J, Zeuzem S.

Med Mal Infect. 2014 Jun;44(6 Suppl):1. doi: 10.1016/S0399-077X(14)70040-X. French. No abstract available.

PMID:
24994127
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk